I keep seeing the senolytic framing for SGLT2 inhibitors pop up in longevity-adjacent spaces and I am trying to figure out how much of it is actual signal versus a reverse-engineered story for cardiovascular and renal outcomes that surprised everyone in the original trials. The steel-manned version of the claim, as best I can reconstruct it: SGLT2is induce a mild, sustained ketogenic and caloric-restriction-mimetic state, AMPK goes up, mTOR comes down, autophagy increases, and senescent cell burden in kidney, vasculature and adipose tissue drops. There are mouse papers showing reduced p16 and p21 expression in kidney cortex after empagliflozin, and a handful of human studies showing reduced markers of senescence-associated secretory phenotype (SASP) in adipose biopsies. So the mechanism is at least plausible. What I cannot get past: 1. The effect size on hard outcomes (EMPA-REG, DAPA-HF, etc.) shows up within weeks to months, which is way too fast for a true clearance-of-senescent-cells story. Dasatinib plus quercetin in mice takes weeks of exposure to move the needle on tissue p16, and that is with a drug pair selected specifically to kill senescent cells. A modest AMPK nudge clearing enough senescent burden to drop heart failure hospitalizations in three months is a big ask. 2. The hemodynamic and natriuretic effects of SGLT2is are large, immediate, and very well characterized. They alone explain a lot of what we see in the trials. “Senolytic” is a much sexier story than “good diuretic with metabolic side benefits,” and sexier stories get repeated. 3. The senescent cell markers used in most of the human work are surrogate at best. p16 in circulating T cells does not necessarily reflect tissue burden. SASP cytokines overlap heavily with generic inflammation markers, which SGLT2is reduce for plenty of non-senolytic reasons. My working hypothesis is that SGLT2is do nudge senescent cell biology in the right direction, probably via the AMPK/autophagy axis, but the magnitude is small and the clinical benefit is mostly hemodynamic plus glucose-lowering plus a real but modest anti-inflammatory effect. Calling them senolytics in the same sentence as D+Q or fisetin overstates what they are doing by an order of magnitude. The test I would actually want to see, and I have not found it: a head-to-head in older adults, empagliflozin vs intermittent D+Q, with paired skin and adipose biopsies at baseline and 6 months, scoring p16/p21 by IHC and measuring SASP locally rather than serum. Until something like that exists I am treating the senolytic framing as a hypothesis people are running with because it fits a narrative, not because the human data forces them to. Happy to be wrong here. If anyone has seen a human study with tissue-level senescence endpoints on an SGLT2i (not just kidney function or serum markers), I would genuinely like the PMID. tl;dr: plausible mechanism, real outcomes, but the speed and size of the clinical benefit looks more like hemodynamics than cellular clearance to me.